Integra LifeSciences reported Q3 2020 revenues of $370.2 million, a decrease of 2.3% on a reported basis and 1.5% organically. GAAP EPS was $0.38, compared to a loss of ($0.32) in Q3 2019, while adjusted EPS was $0.80, up from $0.68. The company's full-year 2020 guidance remains withdrawn.
Reported revenues were $370.2 million, a decrease of 2.3% on a reported basis and a decrease of 1.5% on an organic basis compared to the prior year.
GAAP earnings per diluted share were $0.38, compared to a GAAP loss of ($0.32) in the third quarter of 2019.
Adjusted earnings per diluted share were $0.80, compared to $0.68 in the prior year.
The Company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19 and ongoing variability in the recovery in surgical procedure volumes.
Due to the ongoing uncertainty around the scope and duration of the pandemic and the timing of recovery across the globe, the Company’s guidance for the full-year 2020 remains withdrawn. Barring significant worsening of the pandemic, the Company expects further sequential revenue improvement in the fourth quarter.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance